Phylogica Welcome

Phylogica is developing next generation intracellular biological therapeutics, including its own preclinical Myc-inhibitor oncology payload, using its proprietary best-in-class cell penetrating FPP endosome escape technology. These technologies stem from Phylogicas differentiated Phylomer peptide libraries discovery platform.

OVERVIEW

The web site phylogica.com currently has a traffic classification of zero (the smaller the more users). We have crawled twenty pages inside the website phylogica.com and found fifteen websites interfacing with phylogica.com. We were able to precure one contacts and directions for phylogica.com to help you connect with them. The web site phylogica.com has been on the internet for one thousand two hundred and twenty weeks, twenty-one days, one hour, and twenty-four minutes.
Pages Parsed
20
Links to this site
15
Contacts
1
Addresses
1
Online Since
Feb 2002

PHYLOGICA.COM TRAFFIC

The web site phylogica.com has seen alternating quantities of traffic all through the year.
Traffic for phylogica.com

Date Range

1 week
1 month
3 months
This Year
Last Year
All time
Traffic ranking (by month) for phylogica.com

Date Range

All time
This Year
Last Year
Traffic ranking by day of the week for phylogica.com

Date Range

All time
This Year
Last Year
Last Month

PHYLOGICA.COM HISTORY

The web site phylogica.com was began on on February 14, 2002. This website was updated on the date of March 25, 2014. It will go back on the market on February 13, 2015. As of today, it is one thousand two hundred and twenty weeks, twenty-one days, one hour, and twenty-four minutes old.
REGISTERED
February
2002
UPDATED
March
2014
EXPIRED
February
2015

WEBPAGE PERIOD

23
YEARS
4
MONTHS
22
DAYS

LINKS TO PHYLOGICA.COM

Advances in drug discovery

uk was founded in 1998 to help optimize the drug discovery process. Our aim is to help pharmabiotech companies identify breaking research with therapeutic potential. This blog is an extension to LeadDiscovery acting as a platform for our opinions on research and an on-line forum where scientists and drug development personnel can freely discuss its potential. Sunday, January 17, 2016. In particular, for an. In DMARD-IRs without specifying conventional or biolo.

Phoremost Home Page

Is focused on bringing more effective and affordable targeted medicines to patients. Phenotypic mining for druggable targets. Has developed a next-generation phenotypic screening platform called SITESEEKER to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.

WHAT DOES PHYLOGICA.COM LOOK LIKE?

Desktop Screenshot of phylogica.com Mobile Screenshot of phylogica.com Tablet Screenshot of phylogica.com

CONTACTS

HARMONIC NEW MEDIA

CRAIG HARMAN

PO BOX 414

NORTH PERTH, WA, 6906

AU

PHYLOGICA.COM SERVER

Our crawlers identified that a lone root page on phylogica.com took three thousand two hundred and thirty-five milliseconds to download. I found a SSL certificate, so our crawlers consider this site secure.
Load time
3.235 sec
SSL
SECURE
IP
103.18.109.113

NAME SERVERS

ns-1246.awsdns-27.org
ns-1954.awsdns-52.co.uk
ns-273.awsdns-34.com
ns-549.awsdns-04.net

SERVER SOFTWARE AND ENCODING

We found that this domain is operating the LiteSpeed os.

SITE TITLE

Phylogica Welcome

DESCRIPTION

Phylogica is developing next generation intracellular biological therapeutics, including its own preclinical Myc-inhibitor oncology payload, using its proprietary best-in-class cell penetrating FPP endosome escape technology. These technologies stem from Phylogicas differentiated Phylomer peptide libraries discovery platform.

PARSED CONTENT

The web site phylogica.com had the following in the homepage, "We harness our revolutionary Phylomer intracellular delivery and drug discovery technology to develop next generation treatment solutions for life-threatening diseases." I saw that the webpage stated " Initial and Change of Directors Interest Notices." They also said " Changes to Board and Management. Notice of Change of Interest of Substantial Shareholder. Reaching for previously unreachable intracellular oncology targets. See the things we do."

SEE SIMILAR WEB SITES

Rukhshotul Izalah

Melantjong Murah ke Dunia Bernama Karimun Jawa. Wisata pantai sebenarnya bukanlah wisata top-list dalam daftar tempat-tempat yang ingin kukunjungi sebelum usiaku 40 tahun.

Ирина Богатырева

Свою новую линию флеш-тату Бейонсе продемонстрировала в соблазнительной фотосессии для журнала CR Fashion Book. В этой фотосессии девушка представила результат своей оригинальной и красивой работы. Липчанина посадили на 10 лет за хранение крупной партии наркотиков. Наблюдатели ОБСЕ вновь подверглись обстрелу в Донбассе. Twitter начал удалять ворованные шутки.

PhylomeDB v4 A repository of large scale phylogenetic data

PhylomeDB is a public database for complete catalogs of gene phylogenies. PhylomeDB includes also a public download section with the complete set of trees, alignments and orthology predictions, as well as a web API. That faciliates cross linking trees from external sources. Finally, phylomeDB provides an advanced tree visualization interface based on the ETE toolkit.

Phylon - T Gonzalez.com powered by Phylons Network.com

We are continuously updating this website. If you come across a page or feature that is not functioning properly, please let us. Know You can send us an e-mail at the address listed above, or use our. Thank you for helping us keep our pages. And features working properly! December 12, 2013. Thomas Gonzalez adopted Eli Jeremiah. Gonzalez, and Lillian Faith Gonzalez. The Lord made us a forever family.